nach oben

Erschienen in:

Open Access 01.02.2011 | Clinical Study – Patient Study

Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma

verfasst von: Michael E. Sughrue, Isaac Yang, Ari J. Kane, Shanna Fang, Aaron J. Clark, Derrick Aranda, Igor J. Barani, Andrew T. Parsa

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2011

Abstract

Craniopharyngiomas are locally aggressive tumors which typically are focused in the sellar and suprasellar region near a number of critical neural and vascular structures mediating endocrinologic, behavioral, and visual functions. The present study aims to summarize and compare the published literature regarding morbidity resulting from treatment of craniopharyngioma. We performed a comprehensive search of the published English language literature to identify studies publishing outcome data of patients undergoing surgery for craniopharyngioma. Comparisons of the rates of endocrine, vascular, neurological, and visual complications were performed using Pearson’s chi-squared test, and covariates of interest were fitted into a multivariate logistic regression model. In our data set, 540 patients underwent surgical resection of their tumor. 138 patients received biopsy alone followed by some form of radiotherapy. Mean overall follow-up for all patients in these studies was 54 ± 1.8 months. The overall rate of new endocrinopathy for all patients undergoing surgical resection of their mass was 37% (95% CI = 33–41). Patients receiving GTR had over 2.5 times the rate of developing at least one endocrinopathy compared to patients receiving STR alone or STR + XRT (52 vs. 19 vs. 20%, χ² P < 0.00001). On multivariate analysis, GTR conferred a significant increase in the risk of endocrinopathy compared to STR + XRT (OR = 3.45, 95% CI = 2.05–5.81, P < 0.00001), after controlling for study size and the presence of significant hypothalamic involvement. There was a statistical trend towards worse visual outcomes in patients receiving XRT after STR compared to GTR or STR alone (GTR = 3.5% vs. STR 2.1% vs. STR + XRT 6.4%, P = 0.11). Given the difficulty in obtaining class 1 data regarding the treatment of this tumor, this study can serve as an estimate of expected outcomes for these patients, and guide decision making until these data are available.

Introduction

Craniopharyngiomas are locally aggressive tumors which typically are focused in the sellar and suprasellar region near a number of critical neural and vascular structures mediating endocrinologic, behavioral, and visual functions. Multimodality therapy for these tumors can be challenging, given the significant potential for harm with any intervention involving the structures in this region, as well as the young age of many of the patients with these lesions.

For many years, gross total resection (GTR) was felt to be the treatment of choice, given the better rates of tumor control compared to subtotal resection (STR) alone, and the avoidance of radiotherapy in young patients. Experience with aggressive surgical resection has led some to conclude that a general goal of GTR in all cases might lead to unacceptable rates of endocrinologic and behavioral morbidity, and that GTR could be replaced with subtotal debulking followed by stereotactic conformal radiotherapy [1‐4]. This potential benefit must be tempered against the risk of radiation induced injury to nearby radiosensitive normal structures, notably the optic chiasm [5, 6]. The present study aims to summarize and compare the published literature regarding morbidity resulting from treatment of craniopharyngioma.

Materials and methods

Article selection

Articles were identified via a PubMed search using the key phrases “craniopharyngioma,” alone and in combination with “optic,” “morbidity,” “pituitary,” “hypopituitarism,” “endocrine,” “complications,” “visual,” and “vision.” Inclusion criteria were: (1) All patients had to have follow-up data available. (2) Articles had to have enough information for each patient to be disaggregated. The rationale for the exclusion of aggregated data sets is described below. Exclusion criteria were: (1) Articles that combined patient outcomes of craniopharyngioma with other childhood tumors were excluded, unless there was a clear distinction between the two separate groups of patients. (2) Rathke’s Pouch tumors were excluded from this study. After reviewing these articles, a thorough review of all referenced sources was also performed.

All references that contained disaggregated data specifically addressing complication rates with adequate follow up in patients who had undergone surgical resection with or without fXRT or stereotactic radiosurgery (SRS) as adjuvant or monotherapy were included in our analysis. In addition, we included patients undergoing surgery via the extended transsphenoidal route in the surgery cohort, where appropriate.

Data extraction

Our searches yielded a total of 274 studies [3, 7‐279] (Table 1) reporting data for 8058 non-duplicated craniophayngioma patients. After analyzing the complication rates in aggregated cohorts, we concluded that complication rates were likely underreported in aggregated data sets (for example, the reported rate of endocrinopathy with GTR was 2.1% in the aggregated datasets, compared with a more realistic 52% in series which presented individual patients separately). Thus, we chose to analyze only these disaggregated datasets.

Table 1

Pubmed ID’s of identified studies

102623	3984798	8607079	11322455	15141142	16700314
290201	4084876	8748817	11345343	15185112	16700318
290203	4308176	8869189	11441284	15206435	16798405
290204	4542715	8869774	11465396	15272926	16825115
290207	5059968	8883637	11515727	15290187	16850111
408309	5573248	9007857	11585327	15322844	16888556
430156	5648949	9068702	11685525	15335421	17015135
615967	5821004	9112447	11740179	15367800	17041520
622676	5842310	9224913	11769865	15558704	17042979
928713	6156805	9298276	11810394	15570985	17046151
975700	6168950	9361074	11841735	15670196	17161483
1011020	6293388	9361075	11862438	15681858	17185886
1110394	6381061	9364961	11938361	15759158	17233305
1174243	6470759	9440495	11942362	15800425	17330531
1403127	6511526	9482551	11949829	15807869	17337922
1414528	6657077	9728244	11961313	15851090	17407137
1527612	6673882	9782245	11981627	15871507	17415187
1669245	6833018	9806520	11990811	15895298	17469176
1727168	6853252	9814465	12060820	15928963	17533510
1772600	6886754	9840379	12062594	15931512	17566208
1803868	7099406	9950494	12099569	15957193	17592268
1955511	7104980	9950495	12116534	15959732	17627142
2002381	7105886	10066013	12134929	15959733	17762741
2013769	7121821	10070421	12197795	15959734	18311527
2080379	7264728	10086237	12243827	15959735
2095298	7413035	10232528	12376777	15965667
2116387	7431164	10424206	12382167	15971075
2204689	7438834	10433322	12419438	15989759
2311109	7530989	10445444	12420123	15995885
2352012	7530989	10461071	12447234	16001286
2398383	7568823	10616560	12456941	16028088
2441286	7596502	10616561	12495299	16034620
2494851	7616262	10659012	12507105	16044343
2501242	7619722	10681689	12507107	16055476
2672706	7673031	10690718	12555247	16124175
2689398	7818929	10703499	12677102	16133275
2894566	7841079	10726829	12786772	16133276
2912938	7841080	10760417	12820755	16133277
3336845	7841081	10867561	12823875	16175850
3396018	7841082	10883334	12825216	16216361
3396019	7841084	10892270	12845200	16320025
3442400	7841085	10975938	12922045	16327556
3489356	7885544	11013625	12925239	16383245
3628817	7942198	11014425	14519213	16500745
3712025	8021691	11118572	14558670	16580494
3738985	8027806	11124639	14961770	16630407
3794057	8272006	11131489	14967425	16700308
3799245	8327728	11143262	15035280	16700310
3968554	8422329	11155065	15040718	16700311
3968556	8438080	11234912	15046646	16700313

Disaggregated data useable for analysis were presented for 800 individual patients. Data were stratified into five groups based on treatment paradigm: STR alone, GTR alone, STR plus adjuvant post-operative radiotherapy (STR + XRT), biopsy followed by fractionated radiotherapy (fXRT), or biopsy followed by radiosurgery (SRS) alone. We did not directly compare the radiation only groups (SRS and fXRT) to the surgically treated patients.

Endocrinopathy was defined as the development of any new monohormonal or polyhormonal anterior hypopituitarism, or diabetes insipidus. Vascular injury referred to any gross injury to the circle of Willis or perforating vessel, as well as any reported post-treatment cerebral infarction. Neurologic injury referred to the development of a post-treatment non-endocrine, non-visual neurologic deficit. Visual deterioration was defined as permanent loss or decrease in visual acuity, or a new visual field cut in either eye. Studies which did not present patient data in a way that these variables could reliably be determined were excluded from further analysis.

Statistical analysis

Pearson’s χ² test was used to analyze for differences in categorical factors. Fisher’s exact test was used if there were less than five values per cell. Analysis of variance (ANOVA) was used to evaluate for statistical differences in pre-operative continuous factors, including age and tumor size. Post-hoc between group analyses were performed when the ANOVA demonstrated P < 0.05 using Tukey’s test. All analyses were carried out using SPSS version 16.0 (SPPS, Inc.).

Logistic regression analysis

Univariate analysis was used to identify covariates which might affect the rate of neurologic, endrocrinologic, vascular, or visual complications in these patients. Binary and categorical variables were compared using Pearson’s χ² test, or the χ² test for trend, respectively. Cut-offs for variables were determined empirically by first analyzing the data in smaller categories, and then aggregating groups which seemed statistically homogeneous. Variables which impacted rates of complication with a P = 0.2 or less on univariate analysis were included in stepwise binary logistic regression modeling [280]. All odds ratios on multivariate analysis, reflect the risk of having nonservicable hearing a neurologic or endocrine complication compared to the reference group. Reference groups included the STR + XRT cohort for the extent of resection analysis and the large sample size studies for the surgeon experience analysis. The goodness of fit of the regression model was confirmed by demonstrating a non-significant P-value on the Hosmer-Lemeshow test [280, 281].

We tested interaction terms between each of the three variables to significantly impact hearing on univariate analysis. The statistical significance of the interactions was assessed with the use of backward stepwise regression, in which statistical significance was estimated by means of the likelihood-ratio test to assess the effect of removing interaction terms for all strata of the given variable [280]. After finding that none of the interaction terms would significantly (unadjusted P > 0.2 for all terms) alter the log likelihood of the regression model if removed, we calculated the adjusted odds ratios without adjusting for interactions.

Of note, while tumor size is a variable of interest, it is inconsistently presented in most studies, and we were only able to collect data on tumor size for 87 patients. Because these data were not enough to include in the multivariate regression modeling, we present only univariate data regarding the relationship between tumor size and complications.

Results

Clinical characteristics of included patients

In our data set, 540 patients underwent surgical resection of their tumor. GTR was achieved in 289 cases, while STR was achieved in 251 cases. Of patients receiving STR, 110 patients received fXRT, and 141 did not. Surgical patients in different cohorts did not differ in mean age at the time of surgery, gender distribution, or pre-operative tumor size.

138 patients received biopsy alone followed by some form of radiotherapy. 72/138 of these patients received fXRT, and 66/138 patients received SRS. Age and gender distribution did not differ between patients receiving fXRT and SRS.

The remaining patients did not have adequate data to facilitate our analysis and were excluded. Mean overall follow-up for all patients in these studies was 54 ± 1.8 months.

The mean number of patients per study was 5.8 patients, (range 1–45 patients per study). 34% of the patients in the study came from series of 10 or less patients, 22% came from series of 10–20 patients, and 43% came from series larger than 20 patients. The modest sample sizes in many of the included studies is an inevitable consequence of the decision to use only disaggregated data, as larger studies generally provide summary statistics instead of individual patient data, and as discussed below, frequently do not report rates of morbidity in a way which can be realistically analyzed.

The rates of neurologic injury after treatment for craniopharyngioma

New neurologic deficits were reported in 5.1% of patients undergoing surgery (95% CI = 3.3–7.1), and in 2.2% of patients undergoing fXRT or SRS alone (95% CI = 0–4.6) (Table 2). There was no statistically significant difference in the rates of neurologic deficits between patients receiving GTR alone, STR alone, or STR + XRT (6.9 vs. 4.2 vs. 1.8%, P = NS) in the univariate analysis, or between patients receiving fXRT and those receiving SRS (1.4 vs. 3.0%, P = NS) (Fig. 2).

Table 2

Summary of overall rates of morbidity

	95% CI
Endocrinopathy
Surgery	33–41
fXRT/SRS	8.8–28
Vascular injury
Surgery	0–0.9
fXRT/SRS	0
Neurologic deficit
Surgery	3.3–7.1
fXRT/SRS	0–4.6
Vision deterioration
Surgery	2.1–5.3
fXRT/SRS	3.9–13.4

Interestingly, on multivariate analysis, GTR conferred a significant increase in the risk of neurologic deficits compared to STR + XRT (OR = 5.05, 95% CI = 1.15–22.21, P = 0.03) (Table 5), after controlling for study size.

Gross total resection markedly increases the rate of endocrinopathy

The overall rate of new endocrinopathy for all patients undergoing surgical resection of their mass was 37% (95% CI = 33–41) (Table 2). Table 3 summarizes the rates of individual endocrinopathies. Significant monoendocrinopathies of TSH and ACTH were reported commonly, as was diabetes insipidus (DI). Anterior panhypopituitarism was reported in as many as 11.8% in patients undergoing GTR.

Table 3

Summary of various types of monohormonal and polyhormonal endocrinopathy following treatment of craniopharyngioma

	GTR (%)	STR (%)	STR + XRT (%)	fXRT	SRS (%)
Hyperprolactinemia	0.0	0.0	0.9	N/A	0.0
Hypogonadism	3.5	2.1	1.8	N/A	3.0
Hypothyroid	13.8	5.7	1.8	N/A	7.6
GH deficiency	6.2	1.4	1.8	N/A	0.0
ACTH deficiency	14.5	6.4	0.9	N/A	3.0
Anterior panhypopituitarism	11.8	3.5	10.0	N/A	3.0
DI	18.7	6.4	5.5	N/A	0.0
Obesity	2.1	0.7	2.7	N/A	1.5
Any endocrinopathy	51.9	19.9	20.0	N/A	18.2

Patients receiving GTR had over 2.5 times the rate of developing at least one endocrinopathy compared to patients receiving STR alone or STR + XRT (52 vs. 19 vs. 20%, χ² P < 0.00001) (Fig. 1). The rates of endocrinopathy for patients receiving fXRT alone were not reported, and thus these data were not analyzed.

On multivariate analysis, GTR conferred a significant increase in the risk of endocrinopathy compared to STR + XRT (OR = 3.45, 95% CI = 2.05–5.81, P < 0.00001) (Table 5), after controlling for study size and the presence of significant hypothalamic involvement.

The rates of vascular injury after surgery for craniopharyngioma

Vascular injury was an uncommon complication of craniopharyngioma surgery, occurring in just two cases (95% CI = 0–0.9) (Table 2), both resulting in ischemic cerebral infarction. No vascular complications were reported in any patients undergoing radiation treatment alone.

The rates of visual decline after treatment for craniopharyngioma

Visual decline was reported in 3.7% of patients undergoing surgery (95% CI = 2.1–5.3), and 8.6% of patients undergoing fXRT or SRS alone (95% CI = 3.9–13.4) (Table 2). There was a statistical trend towards worse visual outcomes in patients receiving XRT after STR compared to GTR or STR alone (GTR = 3.5% vs. STR 2.1% vs. STR + XRT 6.4%, P = 0.11). Visual outcomes did not differ between patients receiving fXRT and those receiving SRS (11.1 vs. 6.1%, P = NS) (Fig. 2).

Univariate risk factors for morbidity after craniopharyngioma surgery

Table 4 demonstrates univariate comparisons of rates of morbidities with patients stratified by age, tumor size, and extent of hypothalamic involvement. Note that in our univariate analysis, Patient age was not a significant univariate predictor of any form of complication, regardless of where the cut-off was placed in this analysis (one such analysis is provided in Table 4). Extensive hypothalamic involvement did increase the risk of endocrinologic complications, however this was not an independent predictor of morbidity when extent of resection was controlled for (Table 5).

Table 4

Univariate analyses of the effect of potential confounding variables on rates of neurologic, endocrinologic, vascular, and visual morbidity in the published literature

	Neurologic	Endocrine	Vascular	Visual
# Patients in study
1–10	9%	2%	1%	6%
11–20	2%	7%	0%	2%
21+	1%	1%	0%	4%
	P < 0.001	P < 0.01	P = 0.12	P = 0.45
Patient age
0–2	9%	48%	0%	4%
2.1–5	5%	41%	0%	0%
5.1–10	5%	44%	1%	2%
11–20	5%	34%	0%	2%
21–50	5%	37%	1%	4%
51+	2%	31%	0%	3%
	P = 0.84	P = 0.41	P = 0.85	P = 0.73
Tumor size
<3 cm	0%	36%	0%	6%
≥3 cm	10%	43%	2%	0%
	P = 0.06	P = 0.33	P = 0.59	P = 0.16
Hypothalamic involvement
Minor or none	5%	40%	5%	3%
Extensive	5%	33%	5%	5%
	P = 0.50	P = 0.09	P = 0.43	P = 0.35

Table 5

Multivariate logistic regression demonstrating the risk of neurologic and endocrinologic morbidity controlling for extent of resection, study size, and presence of extensive hypothalamic involvement

	OR	95% CI		P-value
	OR	−	+	P-value
Neurologic
GTR	5.05	1.15	22.21	0.03
STR	2.41	0.45	12.79	0.30
Study size 1–10	2.54	1.02	6.29	0.04
Study size 11–20	0.31	0.06	1.53	0.15
Endocrine
Extensive hypothalamic involvement	1.28	0.78	2.08	0.33
GTR	3.45	2.05	5.81	<0.00001
STR	1.89	1.05	3.38	0.03
Study size 1–10	1.02	0.66	1.58	0.92
Study size 11–20	0.61	0.35	1.05	0.08

Note that the odds ratio for the GTR and STR groups are expressed relative to the STR + XRT group, and that the odds ratios for the study size groups are expressed relative to studies with the group with the largest study size

As stated in the methods, while tumor size is a variable of interest, it is inconsistently presented in most studies, and we were only able to collect data on tumor size for 87 patients. Because these data were not enough to include in the multivariate regression modeling, we present only univariate data regarding the relationship between tumor size and complications. Patients undergoing surgery for tumors with a size greater than or equal to 3 cm experienced a statistical trend towards a higher rate of neurologic complications compared to patients with smaller tumors (10 vs. 0%, P = 0.06) (Table 4). The rates of endocrinologic, vascular, and visual complications were similar between patients with larger and smaller tumors (Fig. 3).

The effect of surgical experience on rates of morbidity following treatment for craniopharyngioma

Surgical experience is generally not specifically reported in craniopharyngioma series in the literature. Using the sample size in these studies as a surrogate for surgical experience, we found a significant reduction in rates of most complications with increasing sample size (Table 4). More specifically, there was a linear decrease in the rates of neurologic complications with increasing study sample size (1–10 patients: 9%, 11–20 patients: 2%, 21+ patients: 1%, P < 0.0001), and a decrease in rates of endocrinopathy favoring studies larger than 20 patients (1–10 patients: 2%, 11–20 patients: 7%, 21+ patients: 1%, P < 0.01). Vascular injuries were also only reported in small series 1–10 patients: 1%, 11–20 patients: 0%, 21+ patients: 0%, P = 0.12), however this did not reach statistical significance due to the small number of events. Rates of visual complications did not differ between groups of different sample size (1–10 patients: 6%, 11–20 patients: 2%, 21+ patients: 4%, P = 0.45).

On multivariate analysis, studies with small sample sizes remained an independent predictor of increased rates of neurologic morbidity compared to those with large sample size (OR = 2.54, 95% CI = 1.02–6.29, P = 0.04) (Table 5), after controlling for treatment paradigm administered. Study sample size was not an independent predictor of endocrinologic morbidity on multivariate analysis.

Discussion

Currently, there are few definitive studies regarding management strategies for patients with craniopharyngiomas. This study aims to utilize a systematic collection of the published data on craniopharyngioma, to critically evaluate the idea that subtotal resection with adjuvant radiotherapy can serve as a desirable replacement for gross total resection, with lower post-surgical rates of monohormonal and panhormonal hypothalamic/pituitary endocrinopathy.

Based on our analyses, endocrinopathy is a common iatrogenic complication of treatment of craniopharyngiomas with either surgical resection or radiosurgery, however it is not unexpectedly higher with surgery. Gross total resection markedly increases the rate of hormonal disturbances compared to subtotal resection with or without radiotherapy, with over half of patients experiencing at least one endocrinopathy, and over 10% of patients being left with panhypopituitarism. Even after correcting for as many covariates as the data would allow, GTR still increased the rate of post-operative endocrinopathy by over three fold. These data support the concept that attempting gross total resection in these lesions is a difficult trade of endocrine function for tumor control, and that subtotal resection might be better for the patient’s overall quality of life. Further, previous work focusing on craniopharyngioma suggests that craniopharyngiomas frequently recur despite GTR, and that subtotal resection followed by adjuvant radiotherapy provides similar rates of tumor control to that achieved with gross total resection [282]. Taken together, these data argue that gross total resection of craniopharyngiomas may not be the best treatment option for most patients, however further work specifically focusing on the quality of life concerns of patients undergoing these treatment paradigms is needed to definitively conclude that STR + XRT is better for the patients than GTR.

The remaining argument against adjuvant radiation in this region is the risk of visual deterioration with administering radiotherapy or radiosurgery in close proximity to the optic apparatus. In our study, all irradiated patient cohorts experienced an increased rate of visual compromise compared to surgery only cohorts. While adjuvant radiotherapy following subtotal cytoreductive surgery did not reach statistical significance for worse visual outcomes, It is possible that a lack of statistical power in our cohort prevented statistical significance that would have been demonstrated by a larger study. It is important to note that this difference might be as large as a 10% in visual decline over GTR at the extremes of the confidence intervals, which would be a serious argument in favor of eliminating the need for XRT with GTR. This idea clearly deserves additional inquiry, especially for driving subtotal resections towards a targeted attack aimed at creating distance between the tumor and the optic apparatus.

Additionally, our analysis demonstrates that experience with craniopharyngiomas matters, and that experienced surgeons have lower rates of complications, even after correcting for tumor characteristics, and surgical philosophy. More specifically, using study size as a surrogate for surgical experience, more experienced surgeons have lower rates of neurologic complications than less experienced surgeons. We speculate that increased familiarity with the pathoanatomy of these tumors, combined with decreased need for brain retraction by experienced surgeons, leads to decreased rates of injury of surrounding neural structures.

Study limitations

While these findings represent a helpful summary of the published literature on this topic, an analysis of published data is limited by the data published by others, and may reflect source study biases. It is impossible for us to control for the quality of the data reported in the literature. For example, the majority of this data set is derived from self-reported outcomes largely assessed by the treating surgeon and colleagues. It is impossible for us to assess or control for the quality of the data reported in the literature, or the unwillingness to report complications. Such omissions would inevitably change the rates reported in our study. Further, subjectively defined variables, such as histologic diagnosis, extent of resection, and the adequacy of radiation therapy likely vary between studies, and we cannot independently confirm the validity of these definitions in other groups’ publications.

Finally, due to the diverse range of data presentation, the number of variables able to be studied and controlled for is limited. Variables that might be of interest which are inconsistently presented across studies cannot be reviewed. Specifically, we cannot completely control for the effect of tumor size on rates of complications, because unfortunately, not everyone publishes these data.

Conclusion

In this study, we summarized and compared the rates of endocrine, neurologic, vascular, and visual complications reported in craniopharyngioma patients. Given the difficulty in obtaining class 1 data regarding the treatment of this tumor, this study can serve as an estimate of expected outcomes for these patients, and guide decision making until these data become available.

Acknowledgments

Dr Parsa is supported, in part, by the Reza and Georgianna Khatib endowed chair in skull base tumor surgery. Dr Sughrue is supported by the AANS NREF. Mr Rutkowski is supported by the Doris Duke foundation. Mr Kane is supported by the Howard Hughes Medical Foundation and the Ivy Foundation.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

e.Med Neurologie & Psychiatrie

Kombi-Abonnement

Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.

Jetzt testen ²

e.Med Neurologie

Kombi-Abonnement

Mit e.Med Neurologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes, den Premium-Inhalten der neurologischen Fachzeitschriften, inklusive einer gedruckten Neurologie-Zeitschrift Ihrer Wahl.

Jetzt testen ³

Habrand JL, Saran F, Alapetite C, Noel G, El Boustany R, Grill J (2006) Radiation therapy in the management of craniopharyngioma: current concepts and future developments. J Pediatr Endocrinol Metab 19 Suppl 1:389–394PubMed

Merchant TE, Kiehna EN, Kun LE, Mulhern RK, Li C, Xiong X, Boop FA, Sanford RA (2006) Phase II trial of conformal radiation therapy for pediatric patients with craniopharyngioma and correlation of surgical factors and radiation dosimetry with change in cognitive function. J Neurosurg 104:94–102PubMed

Minniti G, Saran F, Traish D, Soomal R, Sardell S, Gonsalves A, Ashley S, Warrington J, Burke K, Mosleh-Shirazi A, Brada M (2007) Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. Radiother Oncol 82:90–95PubMedCrossRef

Scarzello G, Buzzaccarini MS, Perilongo G, Viscardi E, Faggin R, Carollo C, Calderone M, Franchi A, Sotti G (2006) Acute and late morbidity after limited resection and focal radiation therapy in craniopharyngiomas. J Pediatr Endocrinol Metab 19 Suppl 1:399–405PubMed

Raimondi AJ, Rougerie J (1994) A critical review of personal experiences with craniopharyngioma: clinical history, surgical technique and operative results. 1983. Pediatr Neurosurg 21:134–150 (discussion 151-134)PubMedCrossRef

Rienstein S, Adams EF, Pilzer D, Goldring AA, Goldman B, Friedman E (2003) Comparative genomic hybridization analysis of craniopharyngiomas. J Neurosurg 98:162–164PubMedCrossRef

Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 46: 291-302; discussion 302-295, 2000

Abe T, Ludecke DK (1999) Transnasal surgery for infradiaphragmatic craniopharyngiomas in pediatric patients. Neurosurgery 44:957–964 (discussion 964-956)PubMedCrossRef

Adamson TE, Wiestler OD, Kleihues P, Yasargil MG (1990) Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J Neurosurg 73:12–17PubMedCrossRef

10.

Adeloye A, Nottidge VA, Udi J (1988) Craniopharyngioma in Nigerian children. Childs Nerv Syst 4:128–134PubMedCrossRef

11.

Agozzino L, Ferraraccio F, Accardo M, Esposito S, Agozzino M, Cuccurullo L (2006) Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas. Ultrastruct Pathol 30:143–150PubMedCrossRef

12.

Albright AL, Hadjipanayis CG, Lunsford LD, Kondziolka D, Pollack IF, Adelson PD (2005) Individualized treatment of pediatric craniopharyngiomas. Childs Nerv Syst 21:649–654PubMedCrossRef

13.

Al-Mefty O, Ayoubi S, Kadri PA (2007) The petrosal approach for the total removal of giant retrochiasmatic craniopharyngiomas in children. J Neurosurg 106:87–92PubMed

14.

al-Mefty O, Kersh JE, Routh A, Smith RR (1990) The long-term side effects of radiation therapy for benign brain tumors in adults. J Neurosurg 73:502–512PubMedCrossRef

15.

Amendola BE, Gebarski SS, Bermudez AG (1985) Analysis of treatment results in craniopharyngioma. J Clin Oncol 3:252–258PubMed

16.

Amendola BE, Wolf A, Coy SR, Amendola MA (2003) Role of radiosurgery in craniopharyngiomas: a preliminary report. Med Pediatr Oncol 41:123–127PubMedCrossRef

17.

Ammirati M, Samii M, Sephernia A (1990) Surgery of large retrochiasmatic craniopharyngiomas in children. Childs Nerv Syst 6:13–17PubMedCrossRef

18.

Anderson CA, Wilkening GN, Filley CM, Reardon MS, Kleinschmidt-DeMasters BK (1997) Neurobehavioral outcome in pediatric craniopharyngioma. Pediatr Neurosurg 26:255–260PubMedCrossRef

19.

Apuzzo ML, Chikovani OK, Gott PS, Teng EL, Zee CS, Giannotta SL, Weiss MH (1982) Transcallosal, interfornicial approaches for lesions affecting the third ventricle: surgical considerations and consequences. Neurosurgery 10:547–554PubMedCrossRef

20.

Aydin Y, Can SM, Gulkilik A, Turkmenoglu O, Alatli C, Ziyal I (1999) Rapid enlargement and recurrence of a preexisting intrasellar craniopharyngioma during the course of two pregnancies. Case report. J Neurosurg 91:322–324PubMedCrossRef

21.

Barajas MA, Ramirez-Guzman G, Rodriguez-Vazquez C, Toledo-Buenrostro V, Velasquez-Santana H, del Robles RV, Cuevas-Solorzano A, Rodriguez-Hernandez G (2002) Multimodal management of craniopharyngiomas: neuroendoscopy, microsurgery, and radiosurgery. J Neurosurg 97:607–609PubMedCrossRef

22.

Barlas O, Bayindir C, Can M (2000) Interstitial irradiation for craniopharyngioma. Acta Neurochir (Wien) 142:389–395CrossRef

23.

Bartlett JR (1971) Craniopharyngiomas—a summary of 85 cases. J Neurol Neurosurg Psychiatry 34:37–41PubMedCrossRef

24.

Barua KK, Ehara K, Kohmura E, Tamaki N (2003) Treatment of recurrent craniopharyngiomas. Kobe J Med Sci 49:123–132PubMed

25.

Baskin DS, Wilson CB (1986) Surgical management of craniopharyngiomas. A review of 74 cases. J Neurosurg 65:22–27PubMedCrossRef

26.

Behari S, Banerji D, Mishra A, Sharma S, Chhabra DK, Jain VK (2003) Intrinsic third ventricular craniopharyngiomas: report on six cases and a review of the literature. Surg Neurol 60:245–252 (discussion 252-243)PubMedCrossRef

27.

Belen D, Er U, Yigitkanli K, Bolay H (2007) Delayed neurotoxic complication of intracavitary bleomycin therapy for craniopharyngioma in a child who had previously undergone radiosurgery. Case report. J Neurosurg 106:391–393PubMedCrossRef

28.

Berlis A, Vesper J, Ostertag C (2006) Stent placement for intracranial cysts by combined stereotactic/endoscopic surgery. Neurosurgery 59:ONS474–479; discussion ONS479-480

29.

Bhagwati SN, Deopujari CE, Parulekar GD (1990) Lamina terminalis approach for retrochiasmal craniopharyngiomas. Childs Nerv Syst 6:425–429PubMedCrossRef

30.

Bianco Ade M, Madeira LV, Rosemberg S, Shibata MK (2006) Cortical seeding of a craniopharyngioma after craniotomy: case report. Surg Neurol 66:437–440 (discussion 440)PubMedCrossRef

31.

Bin-Abbas B, Mawlawi H, Sakati N, Khafaja Y, Chaudhary MA, Al-Ashwal A (2001) Endocrine sequelae of childhood craniopharyngioma. J Pediatr Endocrinol Metab 14:869–874PubMed

32.

Blackburn TP, Doughty D, Plowman PN (1999) Stereotactic intracavitary therapy of recurrent cystic craniopharyngioma by instillation of 90yttrium. Br J Neurosurg 13:359–365PubMedCrossRef

33.

Boch AL, van Effenterre R, Kujas M (1997) Craniopharyngiomas in two consanguineous siblings: case report. Neurosurgery 41:1185–1187PubMedCrossRef

34.

Bohn D, Davids MR, Friedman O, Halperin ML (2005) Acute and fatal hyponatraemia after resection of a craniopharyngioma: a preventable tragedy. QJM 98:691–703PubMedCrossRef

35.

Bremer AM, Nguyen TQ, Balsys R (1984) Therapeutic benefits of combination chemotherapy with vincristine, BCNU, and procarbazine on recurrent cystic craniopharyngioma. A case report. J Neurooncol 2:47–51PubMedCrossRef

36.

Broggi G, Franzini A, Cajola L, Pluchino F (1994) Cell kinetic investigations in craniopharyngioma: preliminary results and considerations. Pediatr Neurosurg 21 Suppl 1:21–23PubMedCrossRef

37.

Buhl R, Nabavi A, Fritsch M, Mehdorn HM (2001) Nasopharyngeal extension of a craniopharyngioma in a 4 year old girl. Acta Neurochir (Wien) 143:1283–1285CrossRef

38.

Bulow B, Attewell R, Hagmar L, Malmstrom P, Nordstrom CH, Erfurth EM (1998) Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. J Clin Endocrinol Metab 83:3897–3904PubMedCrossRef

39.

Burkey BB, Speyer MT, Maciunas RJ, Fitzpatrick JM, Galloway RL Jr, Allen GS (1998) Sublabial, transseptal, transsphenoidal approach to the pituitary region guided by the ACUSTAR I system. Otolaryngol Head Neck Surg 118:191–194PubMedCrossRef

40.

Cabezudo JM, Vaquero J, Areitio E, Martinez R, de Sola RG, Bravo G (1981) Craniopharyngiomas: a critical approach to treatment. J Neurosurg 55:371–375PubMedCrossRef

41.

Caceres A (2005) Intracavitary therapeutic options in the management of cystic craniopharyngioma. Childs Nerv Syst 21:705–718PubMedCrossRef

42.

Caldarelli M, di Rocco C, Papacci F, Colosimo C Jr (1998) Management of recurrent craniopharyngioma. Acta Neurochir (Wien) 140:447–454CrossRef

43.

Caldarelli M, Massimi L, Tamburrini G, Cappa M, Di Rocco C (2005) Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome. Childs Nerv Syst 21:747–757PubMedCrossRef

44.

Calvo FA, Hornedo J, Arellano A, Sachetti A, de la Torre A, Aragon G, Otero J (1983) Radiation therapy in craniopharyngiomas. Int J Radiat Oncol Biol Phys 9:493–496PubMedCrossRef

45.

Cavalheiro S, Dastoli PA, Silva NS, Toledo S, Lederman H, da Silva MC (2005) Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma. Childs Nerv Syst 21:719–724PubMedCrossRef

46.

Cavazzuti V, Fischer EG, Welch K, Belli JA, Winston KR (1983) Neurological and psychophysiological sequelae following different treatments of craniopharyngioma in children. J Neurosurg 59:409–417PubMedCrossRef

47.

Chakrabarti I, Amar AP, Couldwell W, Weiss MH (2005) Long-term neurological, visual, and endocrine outcomes following transnasal resection of craniopharyngioma. J Neurosurg 102:650–657PubMedCrossRef

48.

Gonc EN, Yordam N, Ozon A, Alikasifoglu A, Kandemir N (2004) Endocrinological outcome of different treatment options in children with craniopharyngioma: a retrospective analysis of 66 cases. Pediatr Neurosurg 40:112–119PubMedCrossRef

49.

Gsponer J, De Tribolet N, Deruaz JP, Janzer R, Uske A, Mirimanoff RO, Reymond MJ, Rey F, Temler E, Gaillard RC, Gomez F (1999) Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine (Baltimore) 78:236–269CrossRef

50.

Guidetti B, Fraioli B (1979) Craniopharyngiomas. Results of surgical treatment. Acta Neurochir Suppl (Wien) 28:349–351

51.

Gupta DK, Ojha BK, Sarkar C, Mahapatra AK, Sharma BS, Mehta VS (2006) Recurrence in pediatric craniopharyngiomas: analysis of clinical and histological features. Childs Nerv Syst 22:50–55PubMedCrossRef

52.

Gupta K, Kuhn MJ, Shevlin DW, Wacaser LE (1999) Metastatic craniopharyngioma. AJNR Am J Neuroradiol 20:1059–1060PubMed

53.

Gurkaynak M, Ozyar E, Zorlu F, Akyol FH, Atahan IL (1994) Results of radiotherapy in craniopharyngiomas analysed by the linear quadratic model. Acta Oncol 33:941–943PubMedCrossRef

54.

Habrand JL, Ganry O, Couanet D, Rouxel V, Levy-Piedbois C, Pierre-Kahn A, Kalifa C (1999) The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. Int J Radiat Oncol Biol Phys 44:255–263PubMedCrossRef

55.

Hader WJ, Steinbok P, Hukin J, Fryer C (2000) Intratumoral therapy with bleomycin for cystic craniopharyngiomas in children. Pediatr Neurosurg 33:211–218PubMedCrossRef

56.

Hafez MA, ElMekkawy S, AbdelBadie H, Mohy M, Omar M (2006) Pediatric craniopharyngioma—rationale for multimodal management: the Egyptian experience. J Pediatr Endocrinol Metab 19 Suppl 1:371–380PubMed

57.

Hamamoto Y, Niino K, Adachi M, Hosoya T (2002) MR and CT findings of craniopharyngioma during and after radiation therapy. Neuroradiology 44:118–122PubMedCrossRef

58.

Hamlat A, Morandi X, Riffaud L, Carsin-Nicol B, Haegelen C, Helal H, Brassier G (2008) Transtemporal-transchoroidal approach and its transamygdala extension to the posterior chiasmatic cistern and diencephalo-mesencephalic lesions. Acta Neurochir (Wien) 150:317–327 (discussion 327-318)CrossRef

59.

Hargrave DR (2006) Does chemotherapy have a role in the management of craniopharyngioma? J Pediatr Endocrinol Metab 19 Suppl 1:407–412PubMed

60.

Hasegawa T, Kondziolka D, Hadjipanayis CG, Lunsford LD (2004) Management of cystic craniopharyngiomas with phosphorus-32 intracavitary irradiation. Neurosurgery 54:813–820 (discussion 820-812)PubMedCrossRef

61.

Hoff JT, Patterson RH Jr (1972) Craniopharyngiomas in children and adults. J Neurosurg 36:299–302PubMedCrossRef

62.

Hoffman HJ (1985) Craniopharyngiomas. Can J Neurol Sci 12:348–352PubMed

63.

Hoffman HJ, De Silva M, Humphreys RP, Drake JM, Smith ML, Blaser SI (1992) Aggressive surgical management of craniopharyngiomas in children. J Neurosurg 76:47–52PubMedCrossRef

64.

Honegger J, Buchfelder M, Fahlbusch R (1999) Surgical treatment of craniopharyngiomas: endocrinological results. J Neurosurg 90:251–257PubMedCrossRef

65.

Hoogenhout J, Otten BJ, Kazem I, Stoelinga GB, Walder AH (1984) Surgery and radiation therapy in the management of craniopharyngiomas. Int J Radiat Oncol Biol Phys 10:2293–2297PubMedCrossRef

66.

Hukin J, Steinbok P, Lafay-Cousin L, Hendson G, Strother D, Mercier C, Samson Y, Howes W, Bouffet E (2007) Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience. Cancer 109:2124–2131PubMedCrossRef

67.

Hukin J, Visser J, Sargent M, Goddard K, Fryer C, Steinbok P (2005) Childhood craniopharyngioma: Vancouver experience. Childs Nerv Syst 21:758–765PubMedCrossRef

68.

Im SH, Wang KC, Kim SK, Chung YN, Kim HS, Lee CH, Cho BK (2003) Transsphenoidal microsurgery for pediatric craniopharyngioma: special considerations regarding indications and method. Pediatr Neurosurg 39:97–103PubMedCrossRef

69.

Inoue HK, Fujimaki H, Kohga H, Ono N, Hirato M, Ohye C (1997) Basal interhemispheric supra- and/or infrachiasmal approaches via superomedial orbitotomy for hypothalamic lesions: preservation of hypothalamo-pituitary functions in combination treatment with radiosurgery. Childs Nerv Syst 13:250–256PubMedCrossRef

70.

Isaac MA, Hahn SS, Kim JA, Bogart JA, Chung CT (2001) Management of craniopharyngioma. Cancer J 7:516–520PubMed

71.

Israel ZH, Pomeranz S (1995) Intracranial craniopharyngioma seeding following radical resection. Pediatr Neurosurg 22:210–213PubMedCrossRef

72.

Ito M, Jamshidi J, Yamanaka K (2001) Does craniopharyngioma metastasize? Case report and review of the literature. Neurosurgery 48:933–935 (discussion 935-936)PubMedCrossRef

73.

Ivkov M, Ribaric I, Slavik E, Antunovic V, Samardzic M, Djordjevic M (1979) Surgical treatment of craniopharyngiomas in adults. Acta Neurochir Suppl (Wien) 28:352–356

74.

Jackson AS, St George EJ, Hayward RJ, Plowman PN (2003) Stereotactic radiosurgery. XVII: recurrent intrasellar craniopharyngioma. Br J Neurosurg 17:138–143PubMedCrossRef

75.

Jakacki RI, Cohen BH, Jamison C, Mathews VP, Arenson E, Longee DC, Hilden J, Cornelius A, Needle M, Heilman D, Boaz JC, Luerssen TG (2000) Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas. J Neurosurg 92:255–260PubMedCrossRef

76.

Jeong IH, Lee JK, Moon KS, Joo SP, Kwak HJ, Kim TS, Kim JH, Kim SH (2006) Ectopic recurrence of craniopharyngioma: a case report and review of the literature. J Neurooncol 79:191–195PubMedCrossRef

77.

Jialal I, Reddi K, Omar MA, Van Dellen JR, Joubert SM (1986) Pituitary tumours in African and Indian patients. Trop Geogr Med 38:175–179PubMed

78.

Joki T, Oi S, Babapour B, Kaito N, Ohashi K, Ebara M, Kato M, Abe T (2002) Neuroendoscopic placement of Ommaya reservoir into a cystic craniopharyngioma. Childs Nerv Syst 18:629–633PubMedCrossRef

79.

Jooma R, Kendall BE (1982) Intracranial tumours in the first year of life. Neuroradiology 23:267–274PubMedCrossRef

80.

Julow J, Backlund EO, Lanyi F, Hajda M, Balint K, Nyary I, Szeifert GT (2007) Long-term results and late complications after intracavitary yttrium-90 colloid irradiation of recurrent cystic craniopharyngiomas. Neurosurgery 61:288–295 (discussion 295-286)PubMedCrossRef

81.

Julow J, Lanyi F, Hajda M, Simkovics M, Arany I, Toth S, Pasztor E (1985) The radiotherapy of cystic craniopharyngioma with intracystic installation of 90Y silicate colloid. Acta Neurochir (Wien) 74:94–99CrossRef

82.

Kabil MS, Shahinian HK (2005) Application of the supraorbital endoscopic approach to tumors of the anterior cranial base. J Craniofac Surg 16:1070–1074 (discussion 1075)PubMedCrossRef

83.

Kalapurakal JA, Goldman S, Hsieh YC, Tomita T, Marymont MH (2000) Clinical outcome in children with recurrent craniopharyngioma after primary surgery. Cancer J 6:388–393PubMed

84.

Kalapurakal JA, Goldman S, Hsieh YC, Tomita T, Marymont MH (2003) Clinical outcome in children with craniopharyngioma treated with primary surgery and radiotherapy deferred until relapse. Med Pediatr Oncol 40:214–218PubMedCrossRef

85.

Kang JK, Song JU (1988) Results of the management of craniopharyngioma in children. An endocrinological approach to the treatment. Childs Nerv Syst 4:135–138PubMedCrossRef

86.

Karavitaki N, Brufani C, Warner JT, Adams CB, Richards P, Ansorge O, Shine B, Turner HE, Wass JA (2005) Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 62:397–409CrossRef

87.

Katz EL (1975) Late results of radical excision of craniopharyngiomas in children. J Neurosurg 42:86–93PubMedCrossRef

88.

Kawaguchi T, Fujimura M, Shirane R, Shoji T, Watanabe M, Tominaga T (2005) Ectopic recurrence of craniopharyngioma. J Clin Neurosci 12:307–309PubMedCrossRef

89.

Keohane C, Hally M, Ryder DQ, Buckley TF (1994) Late recurrence of craniopharyngioma in the cerebellopontine angle in a fertile woman. J Neurol Neurosurg Psychiatry 57:873–874PubMedCrossRef

90.

Khafaga Y, Jenkin D, Kanaan I, Hassounah M, Al Shabanah M, Gray A (1998) Craniopharyngioma in children. Int J Radiat Oncol Biol Phys 42:601–606PubMedCrossRef

91.

Kim MS, Lee SI, Sim SH (1999) Brain tumors with cysts treated with Gamma Knife radiosurgery: is microsurgery indicated? Stereotact Funct Neurosurg 72 Suppl 1:38–44PubMedCrossRef

92.

Kim SD, Park JY, Park J, Lee JB, Kim SH, Lim DJ (2007) Radiological findings following postsurgical intratumoral bleomycin injection for cystic craniopharyngioma. Clin Neurol Neurosurg 109:236–241PubMedCrossRef

93.

Kim SK, Wang KC, Shin SH, Choe G, Chi JG, Cho BK (2001) Radical excision of pediatric craniopharyngioma: recurrence pattern and prognostic factors. Childs Nerv Syst 17:531–536 (discussion 537)PubMedCrossRef

94.

Chen C, Okera S, Davies PE, Selva D, Crompton JL (2003) Craniopharyngioma: a review of long-term visual outcome. Clin Experiment Ophthalmol 31:220–228PubMedCrossRef

95.

Chiou SM, Lunsford LD, Niranjan A, Kondziolka D, Flickinger JC (2001) Stereotactic radiosurgery of residual or recurrent craniopharyngioma, after surgery, with or without radiation therapy. Neuro Oncol 3:159–166PubMed

96.

Chung WY, Pan DH, Shiau CY, Guo WY, Wang LW (2000) Gamma knife radiosurgery for craniopharyngiomas. J Neurosurg 93 Suppl 3:47–56PubMed

97.

Chung WY, Pan HC, Guo WY, Shiau CY, Wang LW, Wu HM, Lee LS (1998) Protection of visual pathway in gamma knife radiosurgery for craniopharyngiomas. Stereotact Funct Neurosurg 70 Suppl 1:139–151PubMedCrossRef

98.

Cinalli G, Spennato P, Cianciulli E, Fiorillo A, Di Maio S, Maggi G (2006) The role of transventricular neuroendoscopy in the management of craniopharyngiomas: three patient reports and review of the literature. J Pediatr Endocrinol Metab 19 Suppl 1:341–354PubMed

99.

Clayton PE, Price DA, Shalet SM, Gattemaneni HR (1988) Craniopharyngioma recurrence and growth hormone therapy. Lancet 1:642PubMedCrossRef

100.

Colangelo M, Ambrosio A, Ambrosio C (1990) Neurological and behavioral sequelae following different approaches to craniopharyngioma. Long-term follow-up review and therapeutic guidelines. Childs Nerv Syst 6:379–382PubMedCrossRef

101.

Combs SE, Thilmann C, Huber PE, Hoess A, Debus J, Schulz-Ertner D (2007) Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer 109:2308–2314PubMedCrossRef

102.

Connolly ES Jr, Winfree CJ, Carmel PW (1997) Giant posterior fossa cystic craniopharyngiomas presenting with hearing loss. Report of three cases and review of the literature. Surg Neurol 47:291–299PubMedCrossRef

103.

Couldwell WT, Weiss MH, Rabb C, Liu JK, Apfelbaum RI, Fukushima T (2004) Variations on the standard transsphenoidal approach to the sellar region, with emphasis on the extended approaches and parasellar approaches: surgical experience in 105 cases. Neurosurgery 55:539–547 (discussion 547-550)PubMedCrossRef

104.

Crotty TB, Scheithauer BW, Young WF Jr, Davis DH, Shaw EG, Miller GM, Burger PC (1995) Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 83:206–214PubMedCrossRef

105.

Danoff BF, Cowchock FS, Kramer S (1983) Childhood craniopharyngioma: survival, local control, endocrine and neurologic function following radiotherapy. Int J Radiat Oncol Biol Phys 9:171–175PubMed

106.

Dashora U, Mathias D, James A, Zammit-Maempel I, Perros P (2002) Management of recurrent pituitary cysts with pituitary-nasal drain. Pituitary 5:225–233PubMedCrossRef

107.

Davies MJ, King TT, Metcalfe KA, Monson JP (1997) Intraventricular craniopharyngioma: a long-term follow-up of six cases. Br J Neurosurg 11:533–541PubMedCrossRef

108.

Day JD, Giannotta SL, Fukushima T (1994) Extradural temporopolar approach to lesions of the upper basilar artery and infrachiasmatic region. J Neurosurg 81:230–235PubMedCrossRef

109.

Delitala A, Brunori A, Chiappetta F (2004) Purely neuroendoscopic transventricular management of cystic craniopharyngiomas. Childs Nerv Syst 20:858–862PubMedCrossRef

110.

Demaerel P, Moseley IF, Scaravilli F (1993) Recurrent craniopharyngioma invading the orbit, cavernous sinus and skull base: a case report. Neuroradiology 35:261–263PubMedCrossRef

111.

DeVile CJ, Grant DB, Hayward RD, Stanhope R (1996) Growth and endocrine sequelae of craniopharyngioma. Arch Dis Child 75:108–114PubMedCrossRef

112.

Dhellemmes P, Vinchon M (2006) Radical resection for craniopharyngiomas in children: surgical technique and clinical results. J Pediatr Endocrinol Metab 19 Suppl 1:329–335PubMed

113.

Di Rocco C, Caldarelli M, Tamburrini G, Massimi L (2006) Surgical management of craniopharyngiomas—experience with a pediatric series. J Pediatr Endocrinol Metab 19 Suppl 1:355–366PubMed

114.

Djordjevic M, Djordjevic Z, Janicijevic M, Nestorovic B, Stefanovic B, Ivkov M (1979) Surgical treatment of craniopharyngiomas in children. Acta Neurochir Suppl (Wien) 28:344–347

115.

Economos D (1979) Systemic shunting of residual intraparenchymatous cystic craniopharyngioma. Acta Neurochir Suppl (Wien) 28:363–366

116.

el Gammal T, Brooks BS, Hoffman WH (1989) MR imaging of the ectopic bright signal of posterior pituitary regeneration. AJNR Am J Neuroradiol 10:323–328PubMed

117.

Eldevik OP, Blaivas M, Gabrielsen TO, Hald JK, Chandler WF (1996) Craniopharyngioma: radiologic and histologic findings and recurrence. AJNR Am J Neuroradiol 17:1427–1439PubMed

118.

Elwatidy SM, Jamjoom ZA, Jamjoom AB, Yakoub AO (2002) Craniopharyngioma. Analysis of factors that affect the outcome. Saudi Med J 23:34–38PubMed

119.

Ersahin Y, Yurtseven T, Ozgiray E, Mutluer S (2005) Craniopharyngiomas in children: Turkey experience. Childs Nerv Syst 21:766–772PubMedCrossRef

120.

Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M (1999) Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 90:237–250PubMedCrossRef

121.

Fischer EG, Welch K, Shillito J Jr, Winston KR, Tarbell NJ (1990) Craniopharyngiomas in children. Long-term effects of conservative surgical procedures combined with radiation therapy. J Neurosurg 73:534–540PubMedCrossRef

122.

Fisher PG, Jenab J, Gopldthwaite PT, Tihan T, Wharam MD, Foer DR, Burger PC (1998) Outcomes and failure patterns in childhood craniopharyngiomas. Childs Nerv Syst 14:558–563PubMedCrossRef

123.

Fitzek MM, Linggood RM, Adams J, Munzenrider JE (2006) Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 64:1348–1354PubMedCrossRef

124.

Flickinger JC, Deutsch M, Lunsford LD (1989) Repeat megavoltage irradiation of pituitary and suprasellar tumors. Int J Radiat Oncol Biol Phys 17:171–175PubMed

125.

Flickinger JC, Lunsford LD, Singer J, Cano ER, Deutsch M (1990) Megavoltage external beam irradiation of craniopharyngiomas: analysis of tumor control and morbidity. Int J Radiat Oncol Biol Phys 19:117–122PubMed

126.

Fraioli MF, Santoni R, Fraioli C, Contratti F (2006) “Conservative” surgical approach and early postoperative radiotherapy in a patient with a huge cystic craniopharyngioma. Childs Nerv Syst 22:151–155 (discussion 158-163)PubMedCrossRef

127.

Frank G, Pasquini E, Doglietto F, Mazzatenta D, Sciarretta V, Farneti G, Calbucci F (2006) The endoscopic extended transsphenoidal approach for craniopharyngiomas. Neurosurgery 59:ONS75–83 (discussion ONS75-83)

128.

Freeman CR, Souhami L, Caron JL, Villemure JG, Olivier A, Montes J, Farmer JP, Podgorsak EB (1994) Stereotactic external beam irradiation in previously untreated brain tumors in children and adolescents. Med Pediatr Oncol 22:173–180PubMedCrossRef

129.

Frisen L, Sjostrand J, Norrsell K, Lindgren S (1976) Cyclic compression of the intracranial optic nerve: patterns of visual failure and recovery. J Neurol Neurosurg Psychiatry 39:1109–1113PubMedCrossRef

130.

Garcia-Uria J (1978) Surgical experience with craniopharyngioma in adults. Surg Neurol 9:11–14PubMed

131.

Ghatak NR, White BE (1969) Delayed radiation necrosis of the hypothalamus. Report of a case simulating recurrent craniopharyngioma. Arch Neurol 21:425–430PubMed

132.

Gil Z, Constantini S, Spektor S, Abergel A, Khafif A, Beni-Adani L, Leonor TL, DeRowe A, Fliss DM (2005) Skull base approaches in the pediatric population. Head Neck 27:682–689PubMedCrossRef

133.

Giller CA, Berger BD, Pistenmaa DA, Sklar F, Weprin B, Shapiro K, Winick N, Mulne AF, Delp JL, Gilio JP, Gall KP, Dicke KA, Swift D, Sacco D, Harris-Henderson K, Bowers D (2005) Robotically guided radiosurgery for children. Pediatr Blood Cancer 45:304–310PubMedCrossRef

134.

Gomez-Daspet J, Elko L, Grebenev D, Vesely DL (2002) Survival with serum sodium level of 180 mEq/L: permanent disorientation to place and time. Am J Med Sci 324:321–325PubMedCrossRef

135.

Kobayashi T, Kida Y, Mori Y, Hasegawa T (2005) Long-term results of gamma knife surgery for the treatment of craniopharyngioma in 98 consecutive cases. J Neurosurg 103:482–488PubMed

136.

Kobayashi T, Tanaka T, Kida Y (1994) Stereotactic gamma radiosurgery of craniopharyngiomas. Pediatr Neurosurg 21 Suppl 1:69–74PubMedCrossRef

137.

Kodama T, Matsukado Y, Uemura S (1981) Intracapsular irradiation therapy of craniopharyngiomas with radioactive gold: indication and follow-up results. Neurol Med Chir (Tokyo) 21:49–58CrossRef

138.

Kondziolka D, Nathoo N, Flickinger JC, Niranjan A, Maitz AH, Lunsford LD (2003) Long-term results after radiosurgery for benign intracranial tumors. Neurosurgery 53:815–821 (discussion 821-812)PubMed

139.

Konig A, Ludecke DK, Herrmann HD (1986) Transnasal surgery in the treatment of craniopharyngiomas. Acta Neurochir (Wien) 83:1–7CrossRef

140.

Konovalov AN, Gorelyshev SK (1992) Surgical treatment of anterior third ventricle tumours. Acta Neurochir (Wien) 118:33–39CrossRef

141.

Kramer S, Southard M, Mansfield CM (1968) Radiotherapy in the management of craniopharyngiomas: further experiences and late results. Am J Roentgenol Radium Ther Nucl Med 103:44–52PubMed

142.

Kranzinger M, Jones N, Rittinger O, Pilz P, Piotrowski WP, Manzl M, Galvan G, Kogelnik HD (2001) Malignant glioma as a secondary malignant neoplasm after radiation therapy for craniopharyngioma: report of a case and review of reported cases. Onkologie 24:66–72PubMedCrossRef

143.

Kristopaitis T, Thomas C, Petruzzelli GJ, Lee JM (2000) Malignant craniopharyngioma. Arch Pathol Lab Med 124:1356–1360PubMed

144.

Kulkarni V, Daniel RT, Pranatartiharan R (2000) Spontaneous intraventricular rupture of craniopharyngioma cyst. Surg Neurol 54:249–253 (discussion 253)PubMedCrossRef

145.

Kuwabara S, Seo H, Ishikawa S (1987) Huge, dense, cystic craniopharyngioma with unusual extensions—case report. Neurol Med Chir (Tokyo) 27:37–41CrossRef

146.

Lange M, Kirsch CM, Steude U, Oeckler R (1995) Intracavitary treatment of intrasellar cystic craniopharyngeomas with 90-Yttrium by trans-sphenoidal approach—a technical note. Acta Neurochir (Wien) 135:206–209CrossRef

147.

Lapras C, Patet JD, Mottolese C, Gharbi S, Lapras C Jr (1987) Craniopharyngiomas in childhood: analysis of 42 cases. Prog Exp Tumor Res 30:350–358PubMed

148.

Larijani B, Bastanhagh MH, Pajouhi M, Kargar Shadab F, Vasigh A, Aghakhani S (2004) Presentation and outcome of 93 cases of craniopharyngioma. Eur J Cancer Care (Engl) 13:11–15CrossRef

149.

Laws ER Jr (1994) Transsphenoidal removal of craniopharyngioma. Pediatr Neurosurg 21 Suppl 1:57–63PubMedCrossRef

150.

Laws ER Jr, Morris AM, Maartens N (2003) Gliadel for pituitary adenomas and craniopharyngiomas. Neurosurgery 53:255–269 (discussion 259-260)PubMedCrossRef

151.

Lena G, Paz Paredes A, Scavarda D, Giusiano B (2005) Craniopharyngioma in children: Marseille experience. Childs Nerv Syst 21:778–784PubMedCrossRef

152.

Lessell S (1975) Unilateral exophthalmos. Occurrence after treatment for perichiasmatic neoplasms. JAMA 234:305–306PubMedCrossRef

153.

Lichter AS, Wara WM, Sheline GE, Townsend JJ, Wilson CB (1977) The treatment of craniopharyngiomas. Int J Radiat Oncol Biol Phys 2:675–683PubMedCrossRef

154.

Lin KL, Wang HS, Lui TN (2002) Diagnosis and follow-up of craniopharyngiomas with transcranial Doppler sonography. J Ultrasound Med 21:801–806PubMed

155.

Lippens RJ, Rotteveel JJ, Otten BJ, Merx H (1998) Chemotherapy with Adriamycin (doxorubicin) and CCNU (lomustine) in four children with recurrent craniopharyngioma. Eur J Paediatr Neurol 2:263–268PubMedCrossRef

156.

Liu JM, Garonzik IM, Eberhart CG, Sampath P, Brem H (2002) Ectopic recurrence of craniopharyngioma after an interhemispheric transcallosal approach: case report. Neurosurgery 50:639–644 (discussion 644-635)PubMedCrossRef

157.

Locatelli D, Levi D, Rampa F, Pezzotta S, Castelnuovo P (2004) Endoscopic approach for the treatment of relapses in cystic craniopharyngiomas. Childs Nerv Syst 20:863–867PubMedCrossRef

158.

Long DM, Chou SN (1973) Transcallosal removal of cranio-pharyngiomas within the third ventricle. J Neurosurg 39:563–567PubMedCrossRef

159.

Lonjon M, Dran G, Casagrande F, Vandenbos F, Mas JC, Richelme C (2005) Prenatal diagnosis of a craniopharyngioma: a new case with radical surgery and review. Childs Nerv Syst 21:177–180PubMedCrossRef

160.

Lunsford LD, Pollock BE, Kondziolka DS, Levine G, Flickinger JC (1994) Stereotactic options in the management of craniopharyngioma. Pediatr Neurosurg 21 Suppl 1:90–97PubMedCrossRef

161.

Luu QT, Loredo LN, Archambeau JO, Yonemoto LT, Slater JM, Slater JD (2006) Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J 12:155–159PubMed

162.

Lyen KR, Grant DB (1982) Endocrine function, morbidity, and mortality after surgery for craniopharyngioma. Arch Dis Child 57:837–841PubMedCrossRef

163.

Madhavan M, JG P, Abdullah Jafri J, Idris Z (2005) Intraventricular squamous papillary craniopharyngioma: report of a case with intraoperative imprint cytology. Acta Cytol 49:431–434PubMed

164.

Maira G, Anile C, Albanese A, Cabezas D, Pardi F, Vignati A (2004) The role of transsphenoidal surgery in the treatment of craniopharyngiomas. J Neurosurg 100:445–451PubMedCrossRef

165.

Maira G, Anile C, Colosimo C, Cabezas D (2000) Craniopharyngiomas of the third ventricle: trans-lamina terminalis approach. Neurosurgery 47:857–863 (discussion 863-855)PubMedCrossRef

166.

Maira G, Anile C, Rossi GF, Colosimo C (1995) Surgical treatment of craniopharyngiomas: an evaluation of the transsphenoidal and pterional approaches. Neurosurgery 36:715–724PubMedCrossRef

167.

Maira G, Di Rocco C, Anile C, Roselli R (1982) Hyperprolactinemia as the first symptom of craniopharyngioma. Childs Brain 9:205–210PubMed

168.

Malik JM, Cosgrove GR, VandenBerg SR (1992) Remote recurrence of craniopharyngioma in the epidural space. Case report. J Neurosurg 77:804–807PubMedCrossRef

169.

Maniatis AK, Simmons JH, Zeitler PS (2005) Hypothalamic obesity in a patient with craniopharyngioma: dysregulation of neurohormonal control of energy balance. Curr Opin Pediatr 17:275–279PubMedCrossRef

170.

Maniker AH, Krieger AJ (1996) Rapid recurrence of craniopharyngioma during pregnancy with recovery of vision: a case report. Surg Neurol 45:324–327PubMedCrossRef

171.

Mark RJ, Lutge WR, Shimizu KT, Tran LM, Selch MT, Parker RG (1995) Craniopharyngioma: treatment in the CT and MR imaging era. Radiology 197:195–198PubMed

172.

Mason PW, Krawiecki N, Meacham LR (2002) The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med 156:887–892PubMed

173.

Matarazzo P, Genitori L, Lala R, Andreo M, Grossetti R, de Sanctis C (2004) Endocrine function and water metabolism in children and adolescents with surgically treated intra/parasellar tumors. J Pediatr Endocrinol Metab 17:1487–1495PubMed

174.

Matson DD, Crigler JF Jr (1969) Management of craniopharyngioma in childhood. J Neurosurg 30:377–390PubMedCrossRef

175.

Matthew DJ, Levin M (1986) Pulmonary thromboembolism in children. Intensive Care Med 12:404–406PubMedCrossRef

176.

McMurry FG, Hardy RW Jr, Dohn DF, Sadar E, Gardner WJ (1977) Long term results in the management of craniopharyngiomas. Neurosurgery 1:238–241PubMedCrossRef

177.

Merchant TE, Kiehna EN, Sanford RA, Mulhern RK, Thompson SJ, Wilson MW, Lustig RH, Kun LE (2002) Craniopharyngioma: the St. Jude Children’s Research Hospital experience 1984-2001. Int J Radiat Oncol Biol Phys 53:533–542PubMedCrossRef

178.

Minamida Y, Mikami T, Hashi K, Houkin K (2005) Surgical management of the recurrence and regrowth of craniopharyngiomas. J Neurosurg 103:224–232PubMedCrossRef

179.

Moon SH, Kim IH, Park SW, Kim I, Hong S, Park CI, Wang KC, Cho BK (2005) Early adjuvant radiotherapy toward long-term survival and better quality of life for craniopharyngiomas—a study in single institute. Childs Nerv Syst 21:799–807PubMedCrossRef

180.

Mori K, Handa H, Murata T, Takeuchi J, Miwa S, Osaka K (1980) Results of treatment for craniopharyngioma. Childs Brain 6:303–312PubMed

181.

Mottolese C, Stan H, Hermier M, Berlier P, Convert J, Frappaz D, Lapras C (2001) Intracystic chemotherapy with bleomycin in the treatment of craniopharyngiomas. Childs Nerv Syst 17:724–730PubMedCrossRef

182.

Mottolese C, Szathmari A, Berlier P, Hermier M (2005) Craniopharyngiomas: our experience in Lyon. Childs Nerv Syst 21:790–798PubMedCrossRef

183.

Mudgil AV, Repka MX (2000) Childhood optic atrophy. Clin Experiment Ophthalmol 28:34–37PubMedCrossRef

184.

Muller-Scholden J, Lehrnbecher T, Muller HL, Bensch J, Hengen RH, Sorensen N, Stockhausen HB (2000) Radical surgery in a neonate with craniopharyngioma. Report of a case. Pediatr Neurosurg 33:265–269PubMedCrossRef

185.

Murphy M, Worth RD, Norris JS (2004) ‘Disappearing’ recurrent craniopharyngioma. Br J Neurosurg 18:65PubMedCrossRef

186.

Nimsky C, Ganslandt O, Hofmann B, Fahlbusch R (2003) Limited benefit of intraoperative low-field magnetic resonance imaging in craniopharyngioma surgery. Neurosurgery 53:72–80 (discussion 80-71)PubMedCrossRef

187.

Nishioka H, Ito H, Haraoka J, Hashimoto T, Kato Y (2000) Repeated hemorrhage in ciliated craniopharyngioma—case report. Neurol Med Chir (Tokyo) 40:324–328CrossRef

188.

Niu DM, Guo WY, Pan HC, Wong TT (2002) Rapid enlargement of a residual craniopharyngioma during short-term growth hormone replacement. Childs Nerv Syst 18:164–165PubMedCrossRef

189.

Nomura H, Kurimoto M, Nagai S, Hayashi N, Hirashima Y, Tsukamoto E, Endo S (2002) Multiple intracranial seeding of craniopharyngioma after repeated surgery—case report. Neurol Med Chir (Tokyo) 42:268–271CrossRef

190.

Norris JS, Pavaresh M, Afshar F (1998) Primary transsphenoidal microsurgery in the treatment of craniopharyngiomas. Br J Neurosurg 12:305–312PubMedCrossRef

191.

Novegno F, Di Rocco F, Colosimo C Jr, Lauriola L, Caldarelli M (2002) Ectopic recurrences of craniopharyngioma. Childs Nerv Syst 18:468–473PubMedCrossRef

192.

Nyffeler T, Regard M (2001) Kleptomania in a patient with a right frontolimbic lesion. Neuropsychiatry Neuropsychol Behav Neurol 14:73–76PubMed

193.

Ohmori K, Collins J, Fukushima T (2007) Craniopharyngiomas in children. Pediatr Neurosurg 43:265–278PubMedCrossRef

194.

Onoyama Y, Ono K, Yabumoto E, Takeuchi J (1977) Radiation therapy of craniopharyngioma. Radiology 125:799–803PubMed

195.

Palaoglu S, Akbay A, Mocan G, Onol B, Ozcan OE, Ozgen T, Bertan V (1994) Ossified adamantinous type craniopharyngiomas. A series of 13 patients. Acta Neurochir (Wien) 127:166–169CrossRef

196.

Pan DH, Lee LS, Huang CI, Wong TT (1990) Stereotactic internal irradiation for cystic craniopharyngiomas: a 6-year experience. Stereotact Funct Neurosurg 54–55:525–530PubMedCrossRef

197.

Park DH, Park JY, Kim JH, Chung YG, Lee HK, Lee KC, Suh JK (2002) Outcome of postoperative intratumoral bleomycin injection for cystic craniopharyngioma. J Korean Med Sci 17:254–259PubMed

198.

Pemberton LS, Dougal M, Magee B, Gattamaneni HR (2005) Experience of external beam radiotherapy given adjuvantly or at relapse following surgery for craniopharyngioma. Radiother Oncol 77:99–104PubMedCrossRef

199.

Pereira AM, Schmid EM, Schutte PJ, Voormolen JH, Biermasz NR, van Thiel SW, Corssmit EP, Smit JW, Roelfsema F, Romijn JA (2005) High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clin Endocrinol (Oxf) 62:197–204CrossRef

200.

Plowman PN, Wraith C, Royle N, Grossman AB (1999) Stereotactic radiosurgery. IX. Craniopharyngioma: durable complete imaging responses and indications for treatment. Br J Neurosurg 13:352–358PubMedCrossRef

201.

Pollock BE, Lunsford LD, Kondziolka D, Levine G, Flickinger JC (1995) Phosphorus-32 intracavitary irradiation of cystic craniopharyngiomas: current technique and long-term results. Int J Radiat Oncol Biol Phys 33:437–446PubMedCrossRef

202.

Pollock BE, Natt N, Schomberg PJ (2002) Stereotactic management of craniopharyngiomas. Stereotact Funct Neurosurg 79:25–32PubMedCrossRef

203.

Pomeranz HD, Aldrich EF (2004) Intrachiasmal craniopharyngioma: treatment with a cisternal catheter drainage and radiation. J Neuroophthalmol 24:27–30PubMed

204.

Pritz MB (2002) Ruptured true posterior communicating artery aneurysm and cystic craniopharyngioma. Acta Neurochir (Wien) 144:937–939 (discussion 939)CrossRef

205.

Puget S, Garnett M, Wray A, Grill J, Habrand JL, Bodaert N, Zerah M, Bezerra M, Renier D, Pierre-Kahn A, Sainte-Rose C (2007) Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg 106:3–12PubMed

206.

Ragel BT, Bishop FS, Couldwell WT (2007) Recurrent infrasellar clival craniopharyngioma. Acta Neurochir (Wien) 149:729–730 (discussion 730)CrossRef

207.

Ragoowansi AT, Piepgras DG (1991) Postoperative ectopic craniopharyngioma. Case report. J Neurosurg 74:653–655PubMedCrossRef

208.

Rajan B, Ashley S, Gorman C, Jose CC, Horwich A, Bloom HJ, Marsh H, Brada M (1993) Craniopharyngioma—a long-term results following limited surgery and radiotherapy. Radiother Oncol 26:1–10PubMedCrossRef

209.

Rajan B, Ashley S, Thomas DG, Marsh H, Britton J, Brada M (1997) Craniopharyngioma: improving outcome by early recognition and treatment of acute complications. Int J Radiat Oncol Biol Phys 37:517–521PubMedCrossRef

210.

Ramnarayan R, Sreehari NR, Ninan GK, John KM (2007) Delayed postoperative extradural hematoma. Pediatr Neurosurg 43:113–114PubMedCrossRef

211.

Regine WF, Mohiuddin M, Kramer S (1993) Long-term results of pediatric and adult craniopharyngiomas treated with combined surgery and radiation. Radiother Oncol 27:13–21PubMedCrossRef

212.

Rehman HU, Atkin SL (1999) Sleep disturbances and cardiac arrhythmia after treatment of a craniopharyngioma. J R Soc Med 92:585–586PubMed

213.

Richmond IL, Wara WM, Wilson CB (1980) Role of radiation therapy in the management of craniopharyngiomas in children. Neurosurgery 6:513–517PubMedCrossRef

214.

Richmond IL, Wilson CB (1980) Parasellar tumors in children. II. Surgical management, radiation therapy, and follow-up. Childs Brain 7:85–94PubMed

215.

Rilliet B, Vernet O, Pica A (2005) The Geneva and Lausanne (French-speaking Switzerland) experience: in favor of the transsphenoidal approach when feasible. Childs Nerv Syst 21:725–728PubMedCrossRef

216.

Rodriguez FJ, Scheithauer BW, Tsunoda S, Kovacs K, Vidal S, Piepgras DG (2007) The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol 31:1020–1028PubMedCrossRef

217.

Rudnick EF, DiNardo LJ (2006) Image-guided endoscopic endonasal resection of a recurrent craniopharyngioma. Am J Otolaryngol 27:266–267PubMedCrossRef

218.

Saaf M, Thoren M, Bergstrand CG, Noren G, Rahn T, Tallstedt L, Backlund EO (1989) Treatment of craniopharyngiomas—the stereotactic approach in a ten to twenty-three years’ perspective. II. Psychosocial situation and pituitary function. Acta Neurochir (Wien) 99:97–103CrossRef

219.

Samuels MH, Henry P, Kleinschmidt-Demasters B, Lillehei K, Ridgway EC (1991) Pulsatile prolactin secretion in hyperprolactinemia due to presumed pituitary stalk interruption. J Clin Endocrinol Metab 73:1289–1293PubMedCrossRef

220.

Schefter JK, Allen G, Cmelak AJ, Johnson M, Toms S, Duggan D, Blevins LS (2002) The utility of external beam radiation and intracystic 32P radiation in the treatment of craniopharyngiomas. J Neurooncol 56:69–78PubMedCrossRef

221.

Schulz-Ertner D, Frank C, Herfarth KK, Rhein B, Wannenmacher M, Debus J (2002) Fractionated stereotactic radiotherapy for craniopharyngiomas. Int J Radiat Oncol Biol Phys 54:1114–1120PubMedCrossRef

222.

Scott RM, Hetelekidis S, Barnes PD, Goumnerova L, Tarbell NJ (1994) Surgery, radiation, and combination therapy in the treatment of childhood craniopharyngioma—a 20-year experience. Pediatr Neurosurg 21 Suppl 1:75–81PubMedCrossRef

223.

Sener RN, Kismali E, Akyar S, Selcuki M, Yalman O (1997) Large craniopharyngioma extending to the posterior cranial fossa. Magn Reson Imaging 15:1111–1112PubMedCrossRef

224.

Sepehrnia A, Samii M, Tatagiba M (1991) Management of intracavernous tumours: an 11-year experience. Acta Neurochir Suppl (Wien) 53:122–126

225.

Shapiro K, Till K, Grant DN (1979) Craniopharyngiomas in childhood. A rational approach to treatment. J Neurosurg 50:617–623PubMedCrossRef

226.

Shi XE, Wu B, Zhou ZQ, Fan T, Zhang YL (2006) Microsurgical treatment of craniopharyngiomas: report of 284 patients. Chin Med J (Engl) 119:1653–1663

227.

Shinohara O, Shinagawa T, Kubota C, Oi S (1997) Spontaneous reduction of a recurrent craniopharyngioma in an 8-year-old female patient: case report. Neurosurgery 41:1188–1190PubMedCrossRef

228.

Shirane R, Ching-Chan S, Kusaka Y, Jokura H, Yoshimoto T (2002) Surgical outcomes in 31 patients with craniopharyngiomas extending outside the suprasellar cistern: an evaluation of the frontobasal interhemispheric approach. J Neurosurg 96:704–712PubMedCrossRef

229.

Shirane R, Hayashi T, Tominaga T (2005) Fronto-basal interhemispheric approach for craniopharyngiomas extending outside the suprasellar cistern. Childs Nerv Syst 21:669–678PubMedCrossRef

230.

Shuman AG, Heth JA, Marentette LJ, Blaivas M, Muraszko KM (2007) Extracranial nasopharyngeal craniopharyngioma: case report. Neurosurgery 60:E780–E781 (discussion E781)PubMedCrossRef

231.

Siomin V, Spektor S, Beni-Adani L, Constantini S (2001) Application of the orbito-cranial approach in pediatric neurosurgery. Childs Nerv Syst 17:612–617PubMedCrossRef

232.

Smith AR, Elsheikh TM, Silverman JF (1999) Intraoperative cytologic diagnosis of suprasellar and sellar cystic lesions. Diagn Cytopathol 20:137–147PubMedCrossRef

233.

Smith D, Finucane F, Phillips J, Baylis PH, Finucane J, Tormey W, Thompson CJ (2004) Abnormal regulation of thirst and vasopressin secretion following surgery for craniopharyngioma. Clin Endocrinol (Oxf) 61:273–279CrossRef

234.

Snow A, Gozal E, Malhotra A, Tiosano D, Perlman R, Vega C, Shahar E, Gozal D, Hochberg Z, Pillar G (2002) Severe hypersomnolence after pituitary/hypothalamic surgery in adolescents: clinical characteristics and potential mechanisms. Pediatrics 110:e74PubMedCrossRef

235.

Sorva R, Heiskanen O (1986) Craniopharyngioma in Finland. A study of 123 cases. Acta Neurochir (Wien) 81:85–89CrossRef

236.

Sorva R, Heiskanen O, Perheentupa J (1987) Craniopharyngioma in adults. Ann Clin Res 19:339–343PubMed

237.

Sorva R, Jaaskinen J, Heiskanen O, Perheentupa J (1988) Postoperative computed tomographic control of 38 patients with craniopharyngioma. Surg Neurol 29:115–119PubMedCrossRef

238.

Sosa IJ, Krieger MD, McComb JG (2005) Craniopharyngiomas of childhood: the CHLA experience. Childs Nerv Syst 21:785–789PubMedCrossRef

239.

Srinivasan J, Dailey AT, Berger MS (1999) The bifrontal olfactory nerve-sparing approach to lesions of the suprasellar region in children. Pediatr Neurosurg 30:245–252PubMedCrossRef

240.

Stahnke N, Grubel G, Lagenstein I, Willig RP (1984) Long-term follow-up of children with craniopharyngioma. Eur J Pediatr 142:179–185PubMedCrossRef

241.

Stripp DC, Maity A, Janss AJ, Belasco JB, Tochner ZA, Goldwein JW, Moshang T, Rorke LB, Phillips PC, Sutton LN, Shu HK (2004) Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. Int J Radiat Oncol Biol Phys 58:714–720PubMedCrossRef

242.

Sung DI (1982) Suprasellar tumors in children: a review of clinical manifestations and managements. Cancer 50:1420–1425PubMedCrossRef

243.

Sutton LN, Gusnard D, Bruce DA, Fried A, Packer RJ, Zimmerman RA (1991) Fusiform dilatations of the carotid artery following radical surgery of childhood craniopharyngiomas. J Neurosurg 74:695–700PubMedCrossRef

244.

Svien HJ (1965) Surgical experiences with craniopharyngiomas. J Neurosurg 23:148–155PubMedCrossRef

245.

Sweet WH (1976) Radical surgical treatment of craniopharyngioma. Clin Neurosurg 23:52–79PubMed

246.

Symon L (1983) Microsurgery of the hypothalamus with special reference to craniopharyngioma. Neurosurg Rev 6:43–49PubMedCrossRef

247.

Symon L (1994) An approach to radical excision of craniopharyngioma by the temporal route. Pediatr Neurosurg 21 Suppl 1:64–68PubMedCrossRef

248.

Symon L, Pell MF, Habib AH (1991) Radical excision of craniopharyngioma by the temporal route: a review of 50 patients. Br J Neurosurg 5:539–549PubMedCrossRef

249.

Symon L, Sprich W (1985) Radical excision of craniopharyngioma. Results in 20 patients. J Neurosurg 62:174–181PubMedCrossRef

250.

Taguchi Y, Tanaka K, Miyakita Y, Sekino H, Fujimoto M (2000) Recurrent craniopharyngioma with nasopharyngeal extension. Pediatr Neurosurg 32:140–144PubMedCrossRef

251.

Takahashi H, Yamaguchi F, Teramoto A (2005) Long-term outcome and reconsideration of intracystic chemotherapy with bleomycin for craniopharyngioma in children. Childs Nerv Syst 21:701–704PubMedCrossRef

252.

Tavangar SM, Larijani B, Mahta A, Hosseini SM, Mehrazine M, Bandarian F (2004) Craniopharyngioma: a clinicopathological study of 141 cases. Endocr Pathol 15:339–344PubMedCrossRef

253.

Tena-Suck ML, Salinas-Lara C, Arce-Arellano RI, Rembao-Bojorquez D, Morales-Espinosa D, Sotelo J, Arrieta O (2006) Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas. Clin Neurol Neurosurg 108:661–669PubMedCrossRef

254.

Thomas RF, Monacci WT, Mair EA (2002) Endoscopic image-guided transethmoid pituitary surgery. Otolaryngol Head Neck Surg 127:409–416PubMedCrossRef

255.

Thompson D, Phipps K, Hayward R (2005) Craniopharyngioma in childhood: our evidence-based approach to management. Childs Nerv Syst 21:660–668PubMedCrossRef

256.

Thompson IL, Griffin TW, Parker RG, Blasko JC (1978) Craniopharyngioma: the role of radiation therapy. Int J Radiat Oncol Biol Phys 4:1059–1063PubMed

257.

Thomsett MJ, Conte FA, Kaplan SL, Grumbach MM (1980) Endocrine and neurologic outcome in childhood craniopharyngioma: Review of effect of treatment in 42 patients. J Pediatr 97:728–735PubMedCrossRef

258.

Tomita T, Bowman RM (2005) Craniopharyngiomas in children: surgical experience at Children’s Memorial Hospital. Childs Nerv Syst 21:729–746PubMedCrossRef

259.

Tomita T, McLone DG (1993) Radical resections of childhood craniopharyngiomas. Pediatr Neurosurg 19:6–14PubMedCrossRef

260.

Trejos H, Caceres A, Segura JL (2005) Monstrous craniopharyngioma. Case presentations and term proposal. Childs Nerv Syst 21:1049–1053 (discussion 1054-1045)PubMedCrossRef

261.

Ulfarsson E, Lindquist C, Roberts M, Rahn T, Lindquist M, Thoren M, Lippitz B (2002) Gamma knife radiosurgery for craniopharyngiomas: long-term results in the first Swedish patients. J Neurosurg 97:613–622PubMed

262.

Usanov EI, Hatomkin DM, Nikulina TA, Gorban NA (1999) Craniopharyngioma of the pineal region. Childs Nerv Syst 15:4–7PubMedCrossRef

263.

Van den Berge JH, Blaauw G, Breeman WA, Rahmy A, Wijngaarde R (1992) Intracavitary brachytherapy of cystic craniopharyngiomas. J Neurosurg 77:545–550PubMedCrossRef

264.

Van Effenterre R, Boch AL (2002) Craniopharyngioma in adults and children: a study of 122 surgical cases. J Neurosurg 97:3–11PubMedCrossRef

265.

Varlotto JM, Flickinger JC, Kondziolka D, Lunsford LD, Deutsch M (2002) External beam irradiation of craniopharyngiomas: long-term analysis of tumor control and morbidity. Int J Radiat Oncol Biol Phys 54:492–499PubMedCrossRef

266.

Villani RM, Tomei G, Bello L, Sganzerla E, Ambrosi B, Re T, Giovanelli Barilari M (1997) Long-term results of treatment for craniopharyngioma in children. Childs Nerv Syst 13:397–405PubMedCrossRef

267.

Voges J, Sturm V, Lehrke R, Treuer H, Gauss C, Berthold F (1997) Cystic craniopharyngioma: long-term results after intracavitary irradiation with stereotactically applied colloidal beta-emitting radioactive sources. Neurosurgery 40:263–269 (discussion 269-270)PubMedCrossRef

268.

Vrionis FD, Saatman D, Sorenson J, Brem S (2002) Microscopic paraseptal sphenoidotomy approach for pituitary tumors. Cancer Control 9:223–231PubMed

269.

Vyramuthu N, Benton TF (1983) The management of craniopharyngioma. Clin Radiol 34:629–632PubMedCrossRef

270.

Wara WM, Sneed PK, Larson DA (1994) The role of radiation therapy in the treatment of craniopharyngioma. Pediatr Neurosurg 21 Suppl 1:98–100PubMedCrossRef

271.

Weiner HL, Wisoff JH, Rosenberg ME, Kupersmith MJ, Cohen H, Zagzag D, Shiminski-Maher T, Flamm ES, Epstein FJ, Miller DC (1994) Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 35:1001–1010 (discussion 1010-1001)PubMedCrossRef

272.

Weiss M, Sutton L, Marcial V, Fowble B, Packer R, Zimmerman R, Schut L, Bruce D, D’Angio G (1989) The role of radiation therapy in the management of childhood craniopharyngioma. Int J Radiat Oncol Biol Phys 17:1313–1321PubMedCrossRef

273.

Wen BC, Hussey DH, Staples J, Hitchon PW, Jani SK, Vigliotti AP, Doornbos JF (1989) A comparison of the roles of surgery and radiation therapy in the management of craniopharyngiomas. Int J Radiat Oncol Biol Phys 16:17–24PubMedCrossRef

274.

Xu JG, You C, Cai BW, Jiang S, Sun H, Guo FY, Yang YB, Wu B (2005) Microsurgical resection of craniopharyngioma of the third ventricle via an improved transventricular approach. Chin Med J (Engl) 118:806–811

275.

Yamada Y, Haraoka J, Akimoto J (2006) Ectopic recurrence of craniopharyngioma. Neurol Med Chir (Tokyo) 46:598–600CrossRef

276.

Yu X, Liu Z, Li S (2000) Combined treatment with stereotactic intracavitary irradiation and gamma knife surgery for craniopharyngiomas. Stereotact Funct Neurosurg 75:117–122PubMedCrossRef

277.

Zona G, Spaziante R (2006) Management of cystic craniopharyngiomas in childhood by a transsphenoidal approach. J Pediatr Endocrinol Metab 19 Suppl 1:381–388PubMed

278.

Zuccaro G (2005) Radical resection of craniopharyngioma. Childs Nerv Syst 21:679–690PubMedCrossRef

279.

Zuccaro G, Jaimovich R, Mantese B, Monges J (1996) Complications in paediatric craniopharyngioma treatment. Childs Nerv Syst 12:385–390 (discussion 390-381)PubMedCrossRef

280.

Hosmer DW, Lemeshow S (2000) Applied logistic regression. Wiley, New YorkCrossRef

281.

Hosmer DW, Hjort NL (2002) Goodness-of-fit processes for logistic regression: simulation results. Stat Med 21:2723–2738PubMedCrossRef

282.

Yang I, Sughrue ME, Rutkowski MJ, Kaur R, Ivan ME, Aranda D, Barani IJ, Parsa AT (2010) Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurg Focus 28: E5

Titel: Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma
verfasst von: Michael E. Sughrue
Isaac Yang
Ari J. Kane
Shanna Fang
Aaron J. Clark
Derrick Aranda
Igor J. Barani
Andrew T. Parsa
Publikationsdatum: 01.02.2011
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2011
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0265-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma

Abstract

Introduction

Materials and methods

Article selection

Data extraction

Statistical analysis

Logistic regression analysis

Results

Clinical characteristics of included patients

The rates of neurologic injury after treatment for craniopharyngioma

Gross total resection markedly increases the rate of endocrinopathy

The rates of vascular injury after surgery for craniopharyngioma

The rates of visual decline after treatment for craniopharyngioma

Univariate risk factors for morbidity after craniopharyngioma surgery

The effect of surgical experience on rates of morbidity following treatment for craniopharyngioma

Discussion

Study limitations

Conclusion

Acknowledgments

Open Access

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Neurologie & Psychiatrie

e.Med Neurologie

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Materials and methods

Article selection

Data extraction

Statistical analysis

Logistic regression analysis

Results

Clinical characteristics of included patients

The rates of neurologic injury after treatment for craniopharyngioma

Gross total resection markedly increases the rate of endocrinopathy

The rates of vascular injury after surgery for craniopharyngioma

The rates of visual decline after treatment for craniopharyngioma

Univariate risk factors for morbidity after craniopharyngioma surgery

The effect of surgical experience on rates of morbidity following treatment for craniopharyngioma

Discussion

Study limitations

Conclusion

Acknowledgments

Open Access

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Neurologie & Psychiatrie

e.Med Neurologie

Weitere Artikel der Ausgabe 3/2011

Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors

Variable methylation of the imprinted gene, SNRPN, supports a relationship between intracranial germ cell tumours and neural stem cells

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation

Survival among patients with primary central nervous system lymphoma, 1973–2004

Combined atorvastatin and ramipril mitigate radiation-induced impairment of dentate gyrus neurogenesis

The transglutaminase 2 gene is aberrantly hypermethylated in glioma

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie